Short Interest in 180 Life Sciences Corp. (NASDAQ:ATNF) Expands By 21.0%

180 Life Sciences Corp. (NASDAQ:ATNF) was the target of a significant growth in short interest in the month of September. As of September 30th, there was short interest totalling 73,300 shares, a growth of 21.0% from the September 15th total of 60,600 shares. Based on an average daily volume of 90,100 shares, the days-to-cover ratio is presently 0.8 days. Currently, 14.1% of the shares of the stock are short sold.

180 Life Sciences Price Performance

NASDAQ:ATNF traded up $0.04 during midday trading on Monday, hitting $1.36. 15,920 shares of the stock were exchanged, compared to its average volume of 265,734. The business has a 50-day moving average price of $1.78 and a two-hundred day moving average price of $1.86. 180 Life Sciences has a one year low of $1.16 and a one year high of $11.21.

180 Life Sciences (NASDAQ:ATNF) last posted its quarterly earnings data on Monday, August 12th. The company reported $0.01 earnings per share for the quarter.

180 Life Sciences Company Profile

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor.